Piper Sandler raised the firm’s price target on Merit Medical to $95 from $88 and keeps an Overweight rating on the shares. The Q4 preannouncement reinforced Piper’s positive thesis on shares as management’s quarterly execution has become clockwork, and the firm is optimistic that 2024 will provide more of the same plus Wrapsody-related milestones, the analyst tells investors in a research note. Merit Medical remains a top idea for 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MMSI:
- Merit Medical Announces Projected Preliminary Unaudited Revenue for the Year Ended December 31, 2023 and Plans to Announce Fourth Quarter and Year End 2023 Results and Issue Fiscal Year 2024 Guidance on February 28, 2024
- Merit Medical report FY23 preliminary revenue $1.255B-$1.259B, consensus $1.25B
- Merit Medical upgraded to Buy from Hold at Canaccord
- Merit Medical announces process for CEO succession planning
- Merit Medical Announces Process for Chief Executive Officer Succession Planning
